PL2907521T3 - Nowe mutanty prongf i ich zastosowania w wytwarzaniu beta-ngf - Google Patents
Nowe mutanty prongf i ich zastosowania w wytwarzaniu beta-ngfInfo
- Publication number
- PL2907521T3 PL2907521T3 PL15157320T PL15157320T PL2907521T3 PL 2907521 T3 PL2907521 T3 PL 2907521T3 PL 15157320 T PL15157320 T PL 15157320T PL 15157320 T PL15157320 T PL 15157320T PL 2907521 T3 PL2907521 T3 PL 2907521T3
- Authority
- PL
- Poland
- Prior art keywords
- ngf
- beta
- production
- prongf mutants
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11194208 | 2011-12-19 | ||
| EP12805695.9A EP2672984B1 (en) | 2011-12-19 | 2012-12-19 | Novel prongf mutants and uses thereof in the production of beta-ngf |
| EP15157320.1A EP2907521B1 (en) | 2011-12-19 | 2012-12-19 | Novel prongf mutants and uses thereof in the production of beta-ngf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2907521T3 true PL2907521T3 (pl) | 2018-04-30 |
Family
ID=47428641
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12805695T PL2672984T3 (pl) | 2011-12-19 | 2012-12-19 | Nowe mutanty PRONGF i ich zastosowanie do wytwarzania BETA-NGF |
| PL15157320T PL2907521T3 (pl) | 2011-12-19 | 2012-12-19 | Nowe mutanty prongf i ich zastosowania w wytwarzaniu beta-ngf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12805695T PL2672984T3 (pl) | 2011-12-19 | 2012-12-19 | Nowe mutanty PRONGF i ich zastosowanie do wytwarzania BETA-NGF |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9617322B2 (pl) |
| EP (2) | EP2672984B1 (pl) |
| JP (4) | JP6039146B2 (pl) |
| KR (2) | KR20160120788A (pl) |
| CN (2) | CN104203264B (pl) |
| AU (1) | AU2012357052B2 (pl) |
| BR (1) | BR112014014913B1 (pl) |
| CA (1) | CA2859262C (pl) |
| CY (2) | CY1117016T1 (pl) |
| DK (2) | DK2907521T3 (pl) |
| EA (1) | EA031333B1 (pl) |
| ES (2) | ES2657344T3 (pl) |
| HK (1) | HK1202055A1 (pl) |
| HR (2) | HRP20150900T1 (pl) |
| HU (2) | HUE027245T2 (pl) |
| IL (1) | IL233137A0 (pl) |
| LT (1) | LT2907521T (pl) |
| MX (2) | MX370861B (pl) |
| NO (1) | NO2907521T3 (pl) |
| PL (2) | PL2672984T3 (pl) |
| PT (2) | PT2907521T (pl) |
| RS (2) | RS56893B1 (pl) |
| SG (2) | SG10201605028VA (pl) |
| SI (2) | SI2672984T1 (pl) |
| SM (1) | SMT201500201B (pl) |
| TR (1) | TR201802360T4 (pl) |
| WO (1) | WO2013092776A1 (pl) |
| ZA (1) | ZA201403753B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2657344T3 (es) | 2011-12-19 | 2018-03-02 | Wacker Chemie Ag | Nuevos mutantes de proNGF y usos de los mismos en la producción de beta-NGF |
| WO2015038582A2 (en) * | 2013-09-11 | 2015-03-19 | New York University | Methods and compositions for treating bone diseases |
| EP3406259A1 (en) | 2017-05-24 | 2018-11-28 | Dompé farmaceutici S.p.A. | Neurotrophins for use in the treatment of hearing loss |
| CN108456681B (zh) * | 2018-03-26 | 2019-10-11 | 江苏中新医药有限公司 | 高效表达重组人神经生长因子的基因组合 |
| US20210079053A1 (en) | 2018-04-27 | 2021-03-18 | Chiesi Farmaceutici Spa | Production of nerve growth factor (ngf) and of muteins thereof |
| CN112334151A (zh) * | 2018-06-29 | 2021-02-05 | 学校法人同志社 | 包含恩利卡生的制剂 |
| JP2022502359A (ja) | 2018-09-17 | 2022-01-11 | キエージ・フアルマチエウテイチ・エツセ・ピ・ア | 皮膚科障害の処置のための薬剤 |
| IT201900014646A1 (it) * | 2019-08-12 | 2021-02-12 | Consiglio Nazionale Ricerche | Peptide neurotrofico resistente alle proteasi per il trattamento terapeutico di patologie neurodegenerative e/o cutanee |
| CA3147828A1 (en) * | 2019-09-17 | 2021-03-25 | Bruno Pietro Imbimbo | Agent for use in treatment or prevention of ophthalmic disorders |
| IL302317A (en) | 2020-10-28 | 2023-06-01 | Dompe Farm Spa | Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them |
| EP4039269A1 (en) | 2021-02-05 | 2022-08-10 | Dompe' Farmaceutici S.P.A. | Ngf isoform for use in the treatment of ocular pathologies |
| IL307622A (en) | 2021-04-13 | 2023-12-01 | Domp? Farm S P A | Treatment of neuropathic corneal pain with NGF |
| EP4311554A1 (en) | 2022-07-29 | 2024-01-31 | Dompé farmaceutici S.p.a. | Combination for use in ophthalmology |
| EP4316505A1 (en) | 2022-08-05 | 2024-02-07 | Dompé farmaceutici S.p.a. | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
| EP4342485A1 (en) | 2022-09-23 | 2024-03-27 | Dompe' Farmaceutici S.P.A. | Ngf for the treatment of spasticity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4139000A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf |
| ES2213861T3 (es) | 1998-10-09 | 2004-09-01 | Scil Proteins Gmbh | Procedimiento de obtencion de ngf-beta activa. |
| US20030040082A1 (en) | 2001-02-16 | 2003-02-27 | Mark Tuszynski | Mutant pro-neurotrophin with improved activity |
| US7507799B2 (en) | 2001-05-25 | 2009-03-24 | Cornell Research Foundation, Inc. | High affinity ligand for p75 neurotrophin receptor |
| DE10360483B4 (de) | 2003-12-22 | 2007-11-15 | Scil Proteins Gmbh | Expressionsvektor und dessen Verwendung |
| ES2315842T3 (es) | 2004-01-19 | 2009-04-01 | Nsgene A/S | Celulas terapeuticas humanas que secretan factor de crecimiento nervioso. |
| US20080050776A1 (en) | 2006-05-26 | 2008-02-28 | Kenneth Neet | Stable mutated pro nerve growth factors |
| CN101260398B (zh) * | 2007-03-07 | 2013-06-05 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子基因定位改造动物及其制备方法和应用 |
| ES2657344T3 (es) * | 2011-12-19 | 2018-03-02 | Wacker Chemie Ag | Nuevos mutantes de proNGF y usos de los mismos en la producción de beta-NGF |
-
2012
- 2012-12-19 ES ES15157320.1T patent/ES2657344T3/es active Active
- 2012-12-19 SI SI201230289T patent/SI2672984T1/sl unknown
- 2012-12-19 AU AU2012357052A patent/AU2012357052B2/en active Active
- 2012-12-19 PT PT151573201T patent/PT2907521T/pt unknown
- 2012-12-19 DK DK15157320.1T patent/DK2907521T3/en active
- 2012-12-19 DK DK12805695.9T patent/DK2672984T3/en active
- 2012-12-19 HU HUE12805695A patent/HUE027245T2/en unknown
- 2012-12-19 TR TR2018/02360T patent/TR201802360T4/tr unknown
- 2012-12-19 JP JP2014546588A patent/JP6039146B2/ja active Active
- 2012-12-19 MX MX2017012894A patent/MX370861B/es unknown
- 2012-12-19 RS RS20180159A patent/RS56893B1/sr unknown
- 2012-12-19 US US14/366,460 patent/US9617322B2/en active Active
- 2012-12-19 KR KR1020167027254A patent/KR20160120788A/ko not_active Application Discontinuation
- 2012-12-19 PL PL12805695T patent/PL2672984T3/pl unknown
- 2012-12-19 WO PCT/EP2012/076251 patent/WO2013092776A1/en active Application Filing
- 2012-12-19 EA EA201491155A patent/EA031333B1/ru unknown
- 2012-12-19 NO NO15157320A patent/NO2907521T3/no unknown
- 2012-12-19 CA CA2859262A patent/CA2859262C/en active Active
- 2012-12-19 EP EP12805695.9A patent/EP2672984B1/en active Active
- 2012-12-19 RS RS20150561A patent/RS54220B1/en unknown
- 2012-12-19 CN CN201280062855.6A patent/CN104203264B/zh active Active
- 2012-12-19 CN CN201711352074.1A patent/CN109400693A/zh active Pending
- 2012-12-19 HU HUE15157320A patent/HUE036265T2/hu unknown
- 2012-12-19 ES ES12805695.9T patent/ES2545701T3/es active Active
- 2012-12-19 EP EP15157320.1A patent/EP2907521B1/en active Active
- 2012-12-19 SG SG10201605028VA patent/SG10201605028VA/en unknown
- 2012-12-19 SI SI201231212T patent/SI2907521T1/en unknown
- 2012-12-19 MX MX2014007317A patent/MX353074B/es active IP Right Grant
- 2012-12-19 KR KR1020147019162A patent/KR101837802B1/ko active IP Right Grant
- 2012-12-19 SG SG11201402585PA patent/SG11201402585PA/en unknown
- 2012-12-19 PL PL15157320T patent/PL2907521T3/pl unknown
- 2012-12-19 PT PT128056959T patent/PT2672984E/pt unknown
- 2012-12-19 BR BR112014014913-5A patent/BR112014014913B1/pt active IP Right Grant
- 2012-12-19 LT LTEP15157320.1T patent/LT2907521T/lt unknown
-
2014
- 2014-05-22 ZA ZA2014/03753A patent/ZA201403753B/en unknown
- 2014-06-15 IL IL233137A patent/IL233137A0/en active IP Right Grant
-
2015
- 2015-03-12 HK HK15102539.7A patent/HK1202055A1/xx unknown
- 2015-08-20 SM SM201500201T patent/SMT201500201B/xx unknown
- 2015-08-26 CY CY20151100747T patent/CY1117016T1/el unknown
- 2015-08-26 HR HRP20150900TT patent/HRP20150900T1/hr unknown
- 2015-12-22 US US14/978,407 patent/US10308694B2/en active Active
-
2016
- 2016-11-03 JP JP2016215749A patent/JP6622683B2/ja active Active
-
2018
- 2018-02-21 CY CY20181100195T patent/CY1119926T1/el unknown
- 2018-02-21 HR HRP20180307TT patent/HRP20180307T1/hr unknown
- 2018-08-07 JP JP2018148261A patent/JP2019011330A/ja active Pending
- 2018-08-08 JP JP2018148957A patent/JP2019006781A/ja active Pending
-
2019
- 2019-04-05 US US16/376,969 patent/US20200031893A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180307T1 (hr) | Novi mutanti prongf-a i njihova upotreba u proizvodnji beta-ngf-a | |
| SG2014011746A (en) | Nanostructured articles and methods to make the same | |
| GB2488918B (en) | Sugar mixtures and methods for production and use thereof | |
| SG11201404580QA (en) | Nanostructured materials and methods of making the same | |
| SG11201404488UA (en) | Nanostructured materials and methods of making the same | |
| PL2766682T3 (pl) | Sposób, linia technologiczna i wykorzystanie linii technologicznej do wytwarzania cząstek liofilizowanych | |
| IL230650A (en) | Methylphenidate-drug-mediators and processes for their preparation and use | |
| EP2661419A4 (en) | HIGH-PURITY E-1-CHLORO-3,3,3-TRIFLUORPROPES AND METHOD OF MANUFACTURING THEREOF | |
| HUE042637T2 (hu) | Laminátumok és azok elõállítására szolgáló módszerek | |
| EP2697378A4 (en) | IDENTIFICATION AND USE OF KRP MUTANTS IN PLANTS | |
| EP2791075A4 (en) | SYNTHETIC MARBLE HIGH HARDENING AND METHOD OF MANUFACTURING THEREOF | |
| HK1197179A1 (en) | Methods for the production of a cosmetic composition comprising leukolectin and uses thereof | |
| EP2760284A4 (en) | METHODS FOR ONLINE PRODUCTION OF CHLORAMINE AND USE THEREOF | |
| EP2764121A4 (en) | E1 ENZYME MUTANTS AND USES THEREOF | |
| EP2649217A4 (en) | ARTICLE AND METHOD FOR ITS MANUFACTURE AND USE | |
| EP2654486A4 (en) | STRUCTURED SURFACE WITH SEVERAL COLUMNS AND CAPS AND METHOD FOR THE PRODUCTION THEREOF | |
| PT2864087T (pt) | Material compósito de madeira com aerogéis e respetivo processo de produção e utilização | |
| IL233354A (en) | 2, 6-Dihlo-5-Alkoxy-4-Converted-Pyrimidine, Pyrimidine-Carbaldehyde and Production and Use Methods | |
| PL387453A1 (pl) | Meble korkowe oraz sposób wytwarzania mebli korkowych | |
| IL226234A0 (en) | Nucleons, ribocapsids and methods@לייצורם | |
| GB201016060D0 (en) | Improvements in the measurement and control of process parameters |